> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# West Pharmaceutical Says GLP-1 Surge Had 'Nothing One-Offish' — But Margins Are Not 'The New Floor'
- URL: https://www.bullished.co/west-pharmaceutical-says-glp-1-surge-had-nothing-one-offish-but-margins-are-not-the-new-6401a116/
- Published: 2026-10-29T14:07:00.000Z
- Updated: 2026-10-30T02:19:11.000Z
- Description: West's CEO and CFO said GLP-1 sales growth had no one-time boost, and guided fourth-quarter revenue to $820 million to $830 million.
- Author: Matteo Parrino
- Tags: Earnings, WST, Industry: Healthcare

[West Pharmaceutical](https://www.bullished.co/tag/wst/)'s management told analysts on the [third-quarter earnings call](https://www.benzinga.com/news/26/10/62694662/west-pharmaceutical-servs-q3-2026-earnings-call-transcript?ref=bullished.co) on Thursday that its GLP-1 component surge had no one-time elements, with CEO Michele Lagarde saying there was "nothing one-offish in the quarter." CFO Bob McMahon added that GLP-1 high-value components grew "well into the 30s" organically and made up just under 12% of total revenue.

## Pressed on one-time items

West Pharmaceutical, which makes containment and delivery systems for injectable drugs, was asked by an Evercore ISI analyst whether anything in the record GLP-1 elastomer quarter was a one-off. Lagarde called the drug class a durable growth driver. McMahon said management saw no one-time things, and pointed to the Medicare bridge program, generics outside the US and next-generation molecules as opportunities.

Total third-quarter revenue was [$874 million](https://www.benzinga.com/news/26/10/62694662/west-pharmaceutical-servs-q3-2026-earnings-call-transcript?ref=bullished.co), up 11.9% organically and 8.7% as reported. Adjusted earnings per share were $2.66, up 36% from a year earlier. High-value components revenue was $467 million, up 20% organically, and non-GLP-1 components grew in the high teens.

## Margins: no floor, but more to come

A CJS Securities analyst asked whether the margin jump set a new floor. McMahon replied, "I wouldn't say that this is the new floor," adding that the quarter had [no one-timers](https://www.benzinga.com/news/26/10/62694662/west-pharmaceutical-servs-q3-2026-earnings-call-transcript?ref=bullished.co) and that mix shift and strong volume showed the business's incremental margin strength.

Gross margin was 39.7%, up 310 basis points from a year earlier, and adjusted operating margin was 25.3%, up 420 basis points. McMahon called [margin expansion](https://www.benzinga.com/news/26/10/62694662/west-pharmaceutical-servs-q3-2026-earnings-call-transcript?ref=bullished.co) "one of the underappreciated opportunities for us going forward" and said West is "not done with driving those margins over the next several years."

## A cautious fourth-quarter guide

Management guided fourth-quarter revenue to $820 million to $830 million, or 6% to 7% organic growth, well below the third quarter's pace. McMahon called the guide prudent, saying it absorbs a stronger dollar and the third-quarter pull-forward in West Vantage, its contract-manufacturing segment.

For the full year, West raised revenue guidance to [$3.41 billion](https://markets.ft.com/data/announce/detail?dockey=600-202610290600PR%5FNEWS%5FUSPRX%5F%5F%5F%5FNE84028-1&ref=bullished.co) to $3.42 billion, from $3.345 billion to $3.38 billion, and adjusted EPS to $9.38 to $9.48, from $8.85 to $9.05.

Next year, excluding SmartDose 3.5 revenue, which was $100 million this year, will create a roughly 290 basis point headwind to reported growth, McMahon said.

## Capacity build and the February update

West is starting new investments in high-value finishing capacity in Europe and the US. Lagarde said such projects take 18 to 24 months to come online. McMahon said capital spending should stay within 6% to 8% of revenue, with 2026 at $215 million to $220 million.

West will give 2027 guidance with its fourth-quarter results in February.

West will give its first 2027 outlook in February, including how the new finishing capacity supports growth.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [West Pharmaceutical Servs Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/10/62694662/west-pharmaceutical-servs-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates](https://finance.yahoo.com/markets/stocks/articles/west-pharmaceutical-services-wst-q3-101003271.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [West Pharmaceutical beats top-line and bottom-line estimates; raises FY26 outlook | Seeking Alpha](https://seekingalpha.com/news/4659985-west-pharmaceutical-beats-top-line-and-bottom-line-estimates-raises-fy26-outlook?ref=bullished.co) — seekingalpha.com
- [West Pharmaceutical: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/10/west-pharmaceutical-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [West Reports Third-Quarter 2026 Results – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202610290600PR%5FNEWS%5FUSPRX%5F%5F%5F%5FNE84028-1&ref=bullished.co) — Financial Times

### More on West Pharmaceutical

- [West Pharmaceutical Refinanced $203.0 Million Of 2027 Debt Just Before Its Quarterly Report](https://www.bullished.co/west-pharmaceutical-refinanced-203-0-million-of-2027-debt-just-before-its-quarterly-report-b5e60343/)
- [West Pharmaceutical Stock Surges 7%, Adding $1.9 Billion, As Company Lifts 2026 Outlook](https://www.bullished.co/west-pharmaceutical-stock-surges-7-adding-1-9-billion-as-company-lifts-2026-outlook-f0c470fb/)
- [West Pharmaceutical's New CEO Says The Bar For Acquisitions Is 'Incredibly High' As Customers Cut Supplier Lists](https://www.bullished.co/west-pharmaceuticals-new-ceo-says-the-bar-for-acquisitions-is-incredibly-high-as-customers-6faf3bb0/)

[All West Pharmaceutical (WST) coverage →](https://www.bullished.co/tag/wst/)